Concepedia

LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

Ramez N. Eskander, Michael W. Sill, Austin Miller, Lucas R. Beffa, Richard G. Moore, Joanie Mayer Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, G. Canturia,

Annals of Oncology · 2023 · 19 citations · 1 references

DOIFull text

Open access

Concepts

References

1

LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial

Ramez N. Eskander, Michael W. Sill, Austin Miller et al. · Annals of Oncology · 2023 · 19 citations · Full text

, , +11